BioSpace News Archive

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended March 31, 2021.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company committed to being the leader in responsible pain management, reported its financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Women with platinum resistant ovarian cancer experienced longer progression free survival with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone

Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, announced interim findings from the Phase 2 trial of its selective cortisol modulator miricorilant in patients with presumed NASH.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported financial results for the first quarter of 2021.

ICU Medical, Inc., a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, announced financial results for the quarter ended March 31, 2021.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, provided a business update and reported financial results for the quarter ended March 31, 2021.

Homology Medicines, Inc., a clinical-stage genetic medicines company, announced financial results for the first quarter ended March 31, 2021, and highlighted recent accomplishments.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, announced the appointment of Christy Jones to its Board of Directors.